Aoxing Pharmaceutical a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced the China State Food and Drug Administration (SFDA) granted a Manufacturing License to Hebei Aoxing API Pharmaceutical Company, Ltd., the joint venture between Aoxing Pharma and Macfarlan Smith Ltd, a wholly owned subsidiary of Johnson Matthey Plc.
With the Manufacturing License granted, Hebei Aoxing API Pharmaceucitcal Company submitted Business License application, to manufacture Naloxone Hydrochloride API product, to the China Administrative Bureau of Industry and Commerce.
Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented, "We are pleased to have received notice granting us a Manufacturing License from the SFDA and remain on target to begin producing API for the Chinese market in 2011. The synergies from the venture with Macfarlan Smith continue to be promising. We are excited to further the development process and to help address the need in accessing the appropriate quality and quantity of API for the finished dosage narcotics in China."
Recently Aoxing Phjarma's chemical synthesis laboratories and pilot-manufacturing plant passed GMP inspection.
No comments:
Post a Comment